Press Releases

Latest

Calquence Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukaemia and will stop early
7 May 2019
Qternmet XR approved in the US for the treatment of type-2 diabetes
3 May 2019
AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery
30 April 2019
Lynparza receives positive EU CHMP opinion for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer
29 April 2019
Q1 2019 Results
26 April 2019
Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer
10 April 2019
Positive results from Fasenra Phase II trial in hypereosinophilic syndrome published in New England Journal of Medicine
4 April 2019
Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
1 April 2019
Proposed placing of new ordinary shares
28 March 2019
AstraZeneca and Daiichi Sankyo enter collaboration for novel HER2-targeting antibody-drug conjugate
28 March 2019

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2018 so you should be able to find just what you are looking for.

Explore archive

Contact us

Gonzalo Viña

Head of Global Media Relations

+44 203 749 5916

Rob Skelding

Director Global Media Relations

+44 203 749 5821

Matthew Kent

Director Global Media Relations

+44 203 749 5906

Rebecca Einhorn

Director Global Media Relations

+1 301 398 1802

Jennifer Hursit

Manager Global Media Relations

+442037495762

Christina Malmberg Hägerstrand

Media Relations Director, Sweden and Nordic-Baltic

+46 8 552 53 106

Lotta Sjösten

Manager Media Relations, Sweden

+46 8 553 271 10

US Media Team

+1 302 885 2677

Press Releases

Contact us

Subscribe

Follow us

LinkedIn